Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.


A model-based approach was used to integrate data from a phase II study in order to provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III trial. The exposure-response models demonstrated that an increase in daily steady-state area under the plasma concentration-vs.-time curve (AUC(ss)) of 1 microg x h/ml would increase… (More)
DOI: 10.1038/clpt.2010.106


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics